OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from โ1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
VJET
Catheter Precision, Inc.
There isn't enough reported data to score VJET yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
VJET Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
VJET's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | โ |
| Current | 13x | $31.94 | โ |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
VJET PE Valuation
VJET has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
VJET Forward outlook
There aren't enough analyst estimates for VJET to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus VJET down 159%.
VJET Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$64,805.04 | +$44,178.96 |
| Q2 2023 | -$72,567.99 | +$91,782.01 |
| Q1 2023 | -$96,841.84 | +$164,408.16 |
| Q4 2022 | -$98,705.00 | +$372,495.00 |
| Q3 2020 | -$4,346,250.00 | +$7,528,750.00 |
VJET is still losing money, but far less than before: $64,805.04 per share over the past year, against $11,875,000.00 at its worst in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over VJET on profitability, with a higher operating margin.
VJET Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1M | +381% |
| Q1 2026 | $432K | +202% |
| Q4 2025 | $238K | +60% |
| Q3 2025 | $226K | +135% |
| Q2 2025 | $212K | +128% |
| Q1 2025 | $143K | +74% |
| Q4 2024 | $149K | +16% |
| Q3 2024 | $96K | -28% |
VJET's revenue is recovering but still below its 2019 peak: $1M last quarter, up 381% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -388% | +1822 points |
| Q1 2026 | -537% | +1963 points |
| Q4 2025 | -4143% | -2096 points |
| Q3 2025 | -1337% | +1641 points |
| Q2 2025 | -2210% | +711 points |
| Q1 2025 | -2500% | +690 points |
| Q4 2024 | -2048% | -19 points |
| Q3 2024 | -2978% | -926 points |
VJET's operating margin was โ388% last quarter, up 1822 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over VJET on cash generation, producing positive trailing cash flow while its opponent burns cash.
VJET Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.9M | -$606K |
| Q1 2026 | -$2.8M | -$454K |
| Q4 2025 | -$1.5M | +$1.4M |
| Q3 2025 | -$2.2M | +$585K |
| Q2 2025 | -$2.3M | -$528K |
| Q1 2025 | -$2.3M | -$384K |
| Q4 2024 | -$2.9M | -$957K |
| Q3 2024 | -$2.8M | -$937K |
VJET has burned cash in almost every quarter: โ$9M over the past year, against โ$10M the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
VJET Net Leverage
VJET's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
VJET Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.4 | Oversold |
| Stochastic | 0.7 | Oversold |
VJET's weekly RSI is 27 (oversold) and its Stochastic is 1 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
VJET PE vs Healthcare Sector
VJET has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over VJET on trend strength, trading above more of its moving averages.
VJET Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.92 | 42% below |
| 20 week MA | $2.45 | 78% below |
| 50 week MA | $9.55 | 94% below |
| 100 week MA | $29.5 | 98% below |
| 200 week MA | $689.2 | 100% below |
VJET is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over VJET on returns for 2026, with the stronger performance.
VJET Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $2,113,750.0 | $681,150.0 | -68% |
| 2021 | $681,150.0 | $164,350.0 | -76% |
| 2022 | $164,350.0 | $8,246.0 | -95% |
| 2023 | $8,246.0 | $767.6 | -91% |
| 2024 | $767.6 | $77.3 | -90% |
| 2025 | $77.3 | $16.8 | -78% |
| 2026 YTD | $16.8 | $0.53 | -97% |
VJET has finished every year since 2020 lower, and it's down 97% so far in 2026.